Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 105,179,824
  • Shares Outstanding, K 970,831
  • Annual Sales, $ 24,556 M
  • Annual Income, $ 3,232 M
  • 60-Month Beta 0.20
  • Price/Sales 4.28
  • Price/Cash Flow 15.61
  • Price/Book 40.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 1.47
  • Number of Estimates 4
  • High Estimate 1.49
  • Low Estimate 1.45
  • Prior Year 1.50
  • Growth Rate Est. (year over year) -2.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
105.15 +1.56%
on 07/12/19
117.07 -8.78%
on 06/20/19
-8.44 (-7.32%)
since 06/19/19
3-Month
105.15 +1.56%
on 07/12/19
120.01 -11.02%
on 04/29/19
-8.41 (-7.30%)
since 04/18/19
52-Week
88.17 +21.12%
on 07/23/18
132.13 -19.18%
on 03/26/19
+17.36 (+19.41%)
since 07/19/18

Most Recent Stories

More News
Eli Lilly (LLY) is a Top Dividend Stock Right Now: Should You Buy?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

LLY : 106.79 (-1.43%)
Pain Management Drugs Market to Represent A Significant Expansion $77,131 Million By 2023

accounted for $58,577 million in 2016, and is estimated to reach $77,131 million by 2023, registering a CAGR of 4% from 2017 to 2023. North America was the highest contributor to the pain management drugs...

SRNE : 2.60 (+0.78%)
VRX.TO : 30.80 (-3.33%)
BAYRY : 16.7400 (+0.51%)
ABT : 87.49 (-0.31%)
MRK : 81.39 (-1.57%)
LLY : 106.79 (-1.43%)
PFE : 42.77 (-0.67%)
BMY : 43.33 (-1.63%)
NuCana Initiates Dosing in Phase I Study for Solid Tumors

NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.

MRUS : 15.00 (-0.07%)
LLY : 106.79 (-1.43%)
RGEN : 86.80 (-1.13%)
NCNA : 9.26 (-0.96%)
Global pain management drugs market Industry Analysis and Forecast (2018-2026)

Global pain management drugs market was valued US$ 35.2 Bn in 2017 and is expected to reach US$ 52.6 Bn by 2026, at a CAGR of 5.15% during a forecast period.Pain management is the medical field used for...

VRX.TO : 30.80 (-3.33%)
LLY : 106.79 (-1.43%)
GSK : 40.96 (-1.09%)
PFE : 42.77 (-0.67%)
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer(TM), an Investigational Treatment for Alzheimer's Disease

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a Phase 1 study of ACI-3024, a first-in-class investigational oral small...

ACIU : 5.60 (+2.19%)
LLY : 106.79 (-1.43%)
Change Healthcare Names Diana McKenzie to Board of Directors

Change Healthcare Inc. (Nasdaq: CHNG), a leading independent healthcare technology company, announced today that Diana McKenzie has been appointed to the board of directors effective August 1, 2019. Ms....

CHNG : 13.50 (-0.88%)
LLY : 106.79 (-1.43%)
AMGN : 178.39 (-0.64%)
MET : 49.72 (-0.56%)
Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA

Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.

AZN : 40.12 (-1.50%)
LLY : 106.79 (-1.43%)
AGN : 163.16 (+0.68%)
ALKS : 23.27 (-4.16%)
Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study

Eli Lilly and Company (NYSE: LLY) today announced the presentation of data about personal attitudes toward migraine among people without the disease.1 These data are from the OVERCOME (Observational Survey...

LLY : 106.79 (-1.43%)
Stocks climb to records on hopes for lower interest rates

NEW YORK (AP) — The major U.S. stock indexes closed at record highs on Friday, with the S&P 500 ending above 3,000 for the first time. The market was driven higher by technology, consumer discretionary...

C : 70.92 (-1.21%)
WFC : 46.03 (+0.46%)
JPM : 113.54 (-0.99%)
JNJ : 130.31 (-1.33%)
LLY : 106.79 (-1.43%)
PFE : 42.77 (-0.67%)
After Yesterday's Decline of 2.84%, Eli Lilly & Co Offers Investors Better Value

Eli Lilly & Co (NYSE:LLY) traded in a range yesterday that spanned from a low of $106.23 to a high of $111.99. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $109.20...

LLY : 106.79 (-1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong.

See More Share

Trade LLY with:

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 109.23
1st Resistance Point 108.01
Last Price 106.79
1st Support Level 106.08
2nd Support Level 105.36

See More

52-Week High 132.13
Fibonacci 61.8% 115.34
Fibonacci 50% 110.15
Last Price 106.79
Fibonacci 38.2% 104.96
52-Week Low 88.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar